← Back to Screener
Alto Neuroscience Inc. (ANRO)
Price$19.80
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)25.91%
Price vs S&P 500 (4W)-24.50%
VGM Score68.25
Market Capitalization$704.34M
All Metrics
Book Value / Share (Quarterly)$6.94
Cash Flow / Share (Quarterly)$-1.79
Price vs S&P 500 (YTD)1.82%
EPS (TTM)$-2.45
10-Day Avg Trading Volume0.31M
EPS Excl Extra (TTM)$-2.45
EPS (Annual)$-2.50
ROI (Annual)-37.68%
Cash / Share (Quarterly)$7.52
ROA (Last FY)-34.60%
EBITD / Share (TTM)$-2.55
Cash Flow / Share (Annual)$-1.62
P/B Ratio2.89x
P/B Ratio (Quarterly)2.95x
Net Income / Employee (Annual)$-903,400
ROA (TTM)-38.81%
EPS Incl Extra (Annual)$-2.50
Current Ratio (Annual)15.69x
Quick Ratio (Quarterly)20.11x
3-Month Avg Trading Volume0.29M
52-Week Price Return646.10%
P/S Ratio (Annual)3353.98x
Asset Turnover (Annual)0.01x
52-Week High$28.44
EPS Excl Extra (Annual)$-2.50
26-Week Price Return41.84%
Quick Ratio (Annual)15.58x
13-Week Price Return4.04%
Total Debt / Equity (Annual)0.13x
Current Ratio (Quarterly)20.52x
Enterprise Value$458.93M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-4374.76%
Cash / Share (Annual)$5.53
3-Month Return Std Dev73.03%
Net Income / Employee (TTM)$-1,092,700
ROE (Last FY)-40.56%
EPS Basic Excl Extra (Annual)$-2.50
Total Debt / Equity (Quarterly)0.08x
EPS Incl Extra (TTM)$-2.45
ROI (TTM)-41.78%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)617.89%
Year-to-Date Return12.75%
5-Day Price Return-5.42%
EPS Normalized (Annual)$-2.50
Net Profit Margin (Annual)-4374.76%
Month-to-Date Return-21.78%
EBITD / Share (Annual)$-2.77
Operating Margin (Annual)-5740.95%
LT Debt / Equity (Annual)0.12x
LT Debt / Equity (Quarterly)0.07x
EPS Basic Excl Extra (TTM)$-2.45
P/B Ratio (Annual)3.66x
Book Value / Share (Annual)$4.73
Price vs S&P 500 (13W)-5.70%
Beta2.17x
ROE (TTM)-47.22%
52-Week Low$2.15
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.80est. -0.55
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.31
4.31
4.31
4.31
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ANROAlto Neuroscience Inc. | — | — | B | $19.80 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Alto Neuroscience is a clinical-stage biopharmaceutical company developing personalized psychiatric treatments guided by brain-based biomarkers. The company's pipeline includes multiple programs targeting major depressive disorder and schizophrenia, with candidates including ALTO-100, ALTO-202, ALTO-101, and ALTO-300. Alto's approach aims to match patients with treatments based on individual neurobiology to improve treatment efficacy in psychiatry.